focus -WSS

focus

author：hotspot 2025-09-30 00:48:01 - browse：71

Steven Pearson — ICER President Steven D. Pearson Craig F. Walker/The Boston Globe

Meetings of the Institute for Clinical and Economic Review don’t usually get one’s heart pumping. But a meeting Thursday at the Massachusetts Institute of Technology may prove to be the exception to that rule.

Patients Rising Now, an advocacy group that says it promotes transparency in health care and that is a fierce opponent of ICER’s, is expected to face off with the self-professed “watchdog of drug pricing” as it reviews three drugs for Duchenne muscular dystrophy.

Dozens of Duchenne patients and their families — many of whom also express concern that ICER’s review could undermine insurers’ already tepid interest in the treatments — are also expected to be in attendance.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

WSS

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Idaho abortion case may prompt more restrictions in other states

Readout Newsletter: XBI biotech index, Akero Therapeutics

Designating disabled people as health disparity population is crucial

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Diversifying clinical trials isn't enough to close racial gaps: study

focus

focus

focus

Activists slam private health insurers over coverage restrictions

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

In Memoriam: Notable people who died in 2023

HHS names first

The high cost of giving birth even with insurance

Hospitals warn Medicare's drug payment fix is ‘unlawful’

New air purifier tech could be key to improving indoor air quality

Health and fitness trackers are measuring the wrong things

focus

As JPM 2024 winds down, some health tech firms project optimism

Biden's order seeks to regulate AI risk without stifling innovation

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Traditional Chinese medicine benefits explored in new JAMA study

Cassava reveals details — and problems — with Alzheimer's study

Testing for cancer recurrence creates a new limbo for patients

hotspot

focus

focus

Wikipedia